Search Results

There are 10629 results for: content related to: Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database

  1. You have free access to this content
    Rosuvastatin for lowering lipids

    Intervention Review

    The Cochrane Library

    Stephen P Adams, Sarpreet S Sekhon and James M Wright

    Published Online : 21 NOV 2014, DOI: 10.1002/14651858.CD010254.pub2

  2. ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans

    The Journal of Clinical Pharmacology

    Volume 49, Issue 1, January 2009, Pages: 63–71, Dr Tong Zhu, Dr Walid M. Awni, Dr Balakrishna Hosmane, Dr Maureen T. Kelly, Dr Darryl J. Sleep, Dr James C. Stolzenbach, Dr Katty Wan, Mr Titus O. Chira and Dr Rajendra S. Pradhan

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008325671

  3. Coadministration of Dalcetrapib With Pravastatin, Rosuvastatin, or Simvastatin: No Clinically Relevant Drug-Drug Interactions

    The Journal of Clinical Pharmacology

    Volume 50, Issue 10, October 2010, Pages: 1188–1201, Michael Derks, Markus Abt, Mary Phelan, Lynn Turnbull, Georgina Meneses-Lorente, Nuria Bech, Anne-Marie White and Graeme Parr

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009358709

  4. Statins and the risk of liver injury: a population-based case-control study

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 7, July 2014, Pages: 719–725, Guan-Lin Chen, Fei-Yuan Hsiao, Yaa-Hui Dong, Li-Jiuan Shen and Fe-Lin Lin Wu

    Version of Record online : 14 MAY 2014, DOI: 10.1002/pds.3646

  5. You have free access to this content
    Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor

    Cardiovascular Drug Reviews

    Volume 20, Issue 4, December 2002, Pages: 303–328, Anders G. Olsson, Fergus McTaggart and Ali Raza

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3466.2002.tb00099.x

  6. You have free access to this content
    Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress

    British Journal of Pharmacology

    Volume 164, Issue 2b, September 2011, Pages: 598–606, XY Tian, WT Wong, A Xu, ZY Chen, Y Lu, LM Liu, VW Lee, CW Lau, X Yao and Y Huang

    Version of Record online : 28 AUG 2011, DOI: 10.1111/j.1476-5381.2011.01416.x

  7. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

    Clinical Pharmacology & Therapeutics

    Volume 75, Issue 5, May 2004, Pages: 455–463, Dennis W. Schneck, Bruce K. Birmingham, Julie A. Zalikowski, Patrick D. Mitchell, Yi Wang, Paul D. Martin, Kenneth C. Lasseter, Colin D. A. Brown, Amy S. Windass and Ali Raza

    Version of Record online : 6 MAY 2004, DOI: 10.1016/j.clpt.2003.12.014

  8. Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 50, Issue 9, September 2010, Pages: 1039–1049, Dr Ebba Bergman, Mrs Elin M. Matsson, Dr Mikael Hedeland, Dr Ulf Bondesson, Dr Lars Knutson and Dr Hans Lennernäs

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009357432

  9. The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Health Databases

    Pharmacoepidemiology and Drug Safety

    Volume 17, Issue 10, October 2008, Pages: 953–961, Luis Alberto García-Rodríguez, Antonio González-Pérez, Mary Rose Stang, Mari-Ann Wallander and Saga Johansson

    Version of Record online : 21 APR 2008, DOI: 10.1002/pds.1602

  10. Rosuvastatin blocks hERG current and prolongs cardiac repolarization

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 2, February 2012, Pages: 868–878, Isabelle Plante, Patrick Vigneault, Benoît Drolet and Jacques Turgeon

    Version of Record online : 11 NOV 2011, DOI: 10.1002/jps.22809

  11. Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin

    The Journal of Clinical Pharmacology

    Volume 52, Issue 6, June 2012, Pages: 922–931, Ms Divya Samineni, Dr Pankaj B. Desai, Dr Larry Sallans and Dr Carl J. Fichtenbaum

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011407494

  12. Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans

    Biopharmaceutics & Drug Disposition

    Volume 38, Issue 5, July 2017, Page: 363, Soo Hyeon Bae, Wan-Su Park, Seunghoon Han, Gab-jin Park, Jongtae Lee, Taegon Hong, Sangil Jeon and Dong-Seok Yim

    Version of Record online : 6 FEB 2017, DOI: 10.1002/bdd.2060

  13. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

    Clinical Pharmacology & Therapeutics

    Volume 76, Issue 2, August 2004, Pages: 167–177, Steven G. Simonson, Ali Raza, Paul D. Martin, Patrick D. Mitchell, John A. Jarcho, Colin D. A. Brown, Amy S. Windass and Dennis W. Schneck

    Version of Record online : 15 AUG 2004, DOI: 10.1016/j.clpt.2004.03.010

  14. You have free access to this content
    Additive Effect of Homocysteine- and Cholesterol-Lowering Therapy on Endothelium-Dependent Vasodilation in Patients with Cardiovascular Disease

    Cardiovascular Therapeutics

    Volume 30, Issue 5, October 2012, Pages: 277–286, Kerstin Wustmann, Marco Klaey, Annika Burow, Sidney G. Shaw, Otto M. Hess and Yves Allemann

    Version of Record online : 31 JUL 2011, DOI: 10.1111/j.1755-5922.2011.00272.x

  15. Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 1, January/February 2015, Pages: 33–40, Richard D. Finkelman, Tzung-Dau Wang, Yi Wang, Connie T. Azumaya, Bruce K. Birmingham, Jenny Wissmar and Rogelio Mosqueda-Garcia

    Version of Record online : 27 AUG 2014, DOI: 10.1002/cpdd.135

  16. No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 42, Issue 12, December 2002, Pages: 1352–1357, Dr. Paul D. Martin, Mr. John Kemp, Dr. Aaron L. Dane, Dr. Mike J. Warwick and Dr. Dennis W. Schneck

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270002042012008

  17. You have full text access to this OnlineOpen article
    Pharmacological characterization of mechanisms involved in the vasorelaxation produced by rosuvastatin in aortic rings from rats with a cafeteria-style diet

    Clinical and Experimental Pharmacology and Physiology

    Volume 42, Issue 6, June 2015, Pages: 653–661, Jorge Skiold López-Canales, Jair Lozano-Cuenca, Oscar Alberto López-Canales, José Carlos Aguilar-Carrasco, Lidia Aranda-Zepeda, Pedro López-Sánchez, Enrique Fernando Castillo-Henkel, Ruth Mery López-Mayorga and Ignacio Valencia-Hernández

    Version of Record online : 4 JUN 2015, DOI: 10.1111/1440-1681.12406

  18. You have free access to this content
    Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 321–329, Alicia J. Allred, Carolyn J. Bowen, Jung Wook Park, Bin Peng, Daphne D. Williams, Mary Beth Wire and Edmund Lee

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03972.x

  19. You have free access to this content
    Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

    British Journal of Clinical Pharmacology

    Volume 78, Issue 3, September 2014, Pages: 587–598, Thomayant Prueksaritanont, Xiaoyan Chu, Raymond Evers, Stephanie O. Klopfer, Luzelena Caro, Prajakti A. Kothare, Cynthia Dempsey, Scott Rasmussen, Robert Houle, Grace Chan, Xiaoxin Cai, Robert Valesky, Iain P. Fraser and S. Aubrey Stoch

    Version of Record online : 21 AUG 2014, DOI: 10.1111/bcp.12377

  20. Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

    Clinical Pharmacology & Therapeutics

    Volume 94, Issue 1, July 2013, Pages: 37–51, Y Tomita, K Maeda and Y Sugiyama

    Version of Record online : 7 NOV 2012, DOI: 10.1038/clpt.2012.221